ClinicalTrials.gg
CompletedNCT01495169Updated Jun 13, 2016

Tolerability and Pharmacokinetics of Iloperidone in Adolescent Patients

A Phase 1 interventional study of iloperidone (oral tablet) in Safety and Tolerability of Iloperidone, sponsored by Vanda Pharmaceuticals. Completed at 10 sites in United States. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2016-06-13.

Sponsored by Vanda Pharmaceuticals · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
33
Allocation
Not applicable
Ages
12 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing iloperidone in Schizophrenia — 2 open to participants now, 2 under way, 1 of them phase 3. iloperidone · Schizophrenia.

Enrollment
9th of 11
33 · median 260
Started
2011
with 1 other
Phase 1
3 of 11
none open now
Registered
4th of 11
by date
Lead sponsor
7 of 11
Vanda Pharmaceuticals

Among the 11 studies testing iloperidone in Schizophrenia, this one is the 9th largest by enrollment, is one of 2 that started in 2011, is one of 3 in phase 1, and was the 4th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

2 of the 11 studies testing iloperidone in Schizophrenia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

About iloperidone

iloperidone: first FDA approval 2009 (FANAPT). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 12 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing iloperidone in Schizophrenia, or all of them as a file.
02

Study summary

Tolerability, undertstanding of the action of the drug in the body, and understanding the effect of the drug in adolescent patients needing treatment with an antipsychotic medication

03

Conditions studied

  • Safety and Tolerability of Iloperidone

Keywords

  • Antipsychotic
  • Schizophrenia
  • Bipolar disorder
  • Iloperidone
04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • males or females 12-17 years of age.
  • in a stable housing situation with a guardian/parent who can encourage compliance with the study protocol.
  • with diagnosis of disorder requiring treatment with an antipsychotic agent.
  • having a Children's Global Assessment of Severity Scale (CGAS) of 41 or greater.
  • Heart rate \</=100 beats per minute and >/= 50 beats per minute.

Exclusion criteria

Exclusion Criteria:

  • Patients with mild, moderate or severe mental retardation (i.e., documented IQ \<70), do not have the capacity to assent, cannot understand the , or participate fully in the assessments.
  • Hospitalized due to suicidal ideation or suicidal behavior, history of suicidal ideation within 6 months prior to screening, history of suicidal behavior within 2 years prior to screening.
  • Pregnant, females who can become pregnant and lactating females.
  • Known to iloperidone and to related drugs.
  • Clinical conditions (Neurological, metabolic, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal or urological), which may pose significant risk to patients or impair reliable study participation.
  • Clinically unstable cardiac disease, structural cardiac abnormalities, congential long syndrome, abnormalities at screening (PR interval >240 ms, QTcF >450 ms, QRS duration >/= 100 ms) or arrhythmias.
  • Syncope, near syncope, or palpitations. Other protocol-defined inclusion/exclusion criteria may apply.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    Iloperidone

    Part A (dose-escalation and fixed dose): Eligible patients receive iloperidone 2mg/day (1 mg BID) on day 1, then escalated every day for up to 12days utilizing a forced titration regimen to achieve a maximum dose of 12, 16, 20 or 24 mg/day given BID. Part B (optional extension phase): Patients who successfully complete Part A of the study are eligible to continue treatment with iloperidone for an additional 26 weeks

    Drug: iloperidone (oral tablet)

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics of iloperidone at different dose levels based on AUC (area under the plasma concentration time curve during a dosage interval) Cmax ss (maximum plasma concentration at steady state), Tmax ss (time to Cmax at steady state).

    Pharmacokinetics describes the action of a drug in the body over a period of time. Blood samples are collected to measure plasma concentrations of the study drug at different times after dosing. From the plasma concentration data, AUC, Cmax ss, and Tmax ss are calculated.

    Time frame: Visit 5, 6, 7 (after at least 7 days of iloperidone treatment at the same dose level)

  2. Tolerability of iloperidone at different dose levels

    Frequency of treatment emergent adverse events, frequency of clinically notable changes from baseline in vital signs, electrocardiograms, laboratory tests, and reponses on movement disorder rating scales (Barnes Akathisia Rating Scale, Simpson-Angus Scale) and on a rating scale for suicidal thoughts and behaviors (Columbia Suicide Severity Rating Scale)

    Time frame: 14 days

Secondary outcomes

  1. Number of Patients with Adverse Events, Serious Adverse Events or Death

    Safety and tolerability profile in open-label extension

    Time frame: 26 weeks

  2. Change from baseline in Clinical Global Impression of Improvement Scale (CGI-I)

    The CGI-I is scored from 1 to 7 and assesses the overall degree of illness relative to baseline. A CGI-I rating of 4 is equivalent to "no change." Ratings less than 4 are equivalent to "improvement" and ratings of more than 4 are equivalent to "worsening."

    Time frame: Baseline, then Weekly for 2 weeks, then every 2-4 weeks for 26 weeks

  3. Change from baseline in the Children's Global Asessment Scale (CGAS

    The CGAS) is a numeric scale (1 through 100) used to rate the general functioning of children; high scores indicate better functioning.

    Time frame: Baseline, then Weekly for 2 weeks, then every 2-4 weeks for 26 weeks

  4. Effect of iloperidone on QT, QT beat-to-beat (QTbtb), QT corrected using the Fridericia formulat (QTcF), QT corrected using the Bazett formula (QTcB), individual based correct QT (QTcI)

    Patients wear a holter monitor for \~24 hours during the baseline period, for an additional 4 hours after the first dose, and for \~13 hours after they have been on the same dose for at least 7 days to compare how the heart beats before and after the study drug is taken. The holter monitor transmits continuous data to a computer on how the heart beats for the time when the monitor is on and is a better measurement than data collected by a traditional electrocardiogram (ECG), which provides data on a limited number of heart beats over a short period of time.

    Time frame: Baseline (24 hours), Visit 3 (4-hours post initial dose), and Visit 7 (13 hours

  5. Clinically notable changes from baseline on electrocardiogram (ECG) parameters (QTcF, QTcB, QRS, PR, heart rate)

    Three ECGs are obtained for each assessment. The values are averaged for each ECG parameter (QTcF, QTcB, QRS, PR interval, heart rateare) and clinically notable changes from baseline and new or worsening heart rhythm disorders are identified

    Time frame: Screening, baseline, 5x over 2 weeks, then every 2-4 weeks for 26 weeks

07

Study locations

10 sites
  • Novartis Investigative Site
    Costa Mesa, California 92626, United States
  • Novartis Investigative Site
    North Miami, Florida 33161, United States
  • Novartis Investigative Site
    Atlanta, Georgia 30308, United States
  • Novartis Investigative Site
    Coeur d'Alene, Idaho 83814, United States
  • Novartis Investigative Site
    Baltimore, Maryland 21205, United States
  • Novartis Investigative Site
    St. Louis, Missouri 63044, United States
  • Novartis Investigative Site
    Marlton, New Jersey 08053, United States
  • Novartis Investigative Site
    Cincinnati, Ohio 45219, United States
  • Novartis Investigative Site
    Cleveland, Ohio 44106-5000, United States
  • Novartis Investigative Site
    Salt Lake City, Utah 84106, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2011, a primary completion of Feb 2015 and a completion of Feb 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2011
First posted
Dec 19, 2011
Start
Oct 2011
Primary completionActual
Feb 2015
CompletionActual
Feb 2015
Last update
Jun 13, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 13, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01495169
Responsible party
Sponsor
First posted
Dec 19, 2011
Start date
Oct 2011
Primary completion
Feb 2015
Completion
Feb 2015
Last update
Jun 13, 2016

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Iloperidone

Start the discussion